| abstract |
(57) [Summary] B is O or CH 2 ; X is selected from NR 1 R 2 , SR 1 and C 1 -C 7 alkyl; Y is selected from SR 1 , NR 1 R 2 , and C 1 -C 7 alkyl; R 1 and R 2 are each selected on independently alkyl chain H or optionally or within the alkyl chain O, S, from C 1 -C 7 alkyl substituted with one or more N or halogen; R 3 and R 4 is either H or R 3 and R 4 together form a bond; A is COOH, C (O) NH (CH 2 ) p COOH, C (O) N [(CH 2 ) q COOH] 2 , C (O) NHCH (COOH) (CH 2 ) r COOH or 5-tetrazolyl, wherein p, q and r are each independently 1, 2 or 3] Pharmaceutically acceptable salts and prodrugs thereof, pharmaceutical compositions containing the new compounds, and the use of the compounds in therapy. New intermediates for new compounds are also included. The new compounds are particularly useful in preventing platelet aggregation. |